Hyderabad News Desk

DelveInsight’s, “Metastatic Melanoma Pipeline Insight 2023” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Metastatic Melanoma pipeline landscape. It covers the Metastatic Melanoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Melanoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Metastatic Melanoma Pipeline Report

• DelveInsight’s Metastatic Melanoma pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Metastatic Melanoma treatment.
• The leading companies working in the Metastatic Melanoma Market include Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralytics, Merck & Co., Neon Therapeutics, BioNTech, Bristol-Myers Squibb, Ono Pharmaceuticals, Cytovation AS, and others.
• Promising Metastatic Melanoma Pipeline Therapies in the various stages of development include TLPLDC Vaccine, EVX-01, Pembrolizumab 25 MG/ML, Nivolumab, IN10018, Cobimetinib, and others.
• November 2023: Amgen announced a study of Phase 3 clinical trials for ABP 206 and Nivolumab. The purpose of this study is to assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma. A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Treatment-Naïve Unresectable or Metastatic Melanoma.
• October 2023: BioNTech US Inc. announced a study of Phase 1 clinical trials for NEO-PTC-01 and IL-2. The study will be conducted in two parts, Part 1 (Dose Finding) and Part 2 (Dose Expansion). The dose-finding part of the study will test two doses of NEO-PTC-01 and will be structured according to a 3+3 dose escalation design. After the highest tolerated NEO-PTC-01 dose is identified, 2 additional evaluations in Part 1 are planned, a cohort to investigate NEO-PTC-01 in combination with interleukin (IL)-2 and another cohort introducing α programmed cell death protein 1 (αPD-1) therapy. The dose expansion part of the study will test the dose deemed to be safe in the dose-finding part of the study in an expanded cohort of patients to further define the safety of NEO-PTC-01.
• October 2023: Obsidian Therapeutics Inc. announced a study of Phase 1 & 2 clinical trials for OBX-115. This is a study to investigate the safety and efficacy of an investigational regimen, OBX-115, in adult participants with advanced/metastatic melanoma. A Phase 1/2, Open-Label Study to Investigate the Safety and Efficacy of Membrane Bound IL15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) In Participants With Unrespectable or Metastatic Melanoma Resistant to Checkpoint Inhibitors and After BRAF-MEK Targeting Therapy in Participants With BRAF Mutated Melanoma.

Request a sample and discover the recent advances in Metastatic Melanoma Treatment Drugs @ Metastatic Melanoma Pipeline Report

In the Metastatic Melanoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic Melanoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Metastatic Melanoma Overview

Melanoma is the third most common cutaneous malignancy after basal cell carcinoma and squamous cell carcinoma. Melanoma is the fifth most common malignancy in males and sixth most common malignancy in females. Metastatic melanoma is a disease that occurs when the cancerous cells from the original tumor (primary tumor) get loose, spread by traveling through the lymph or blood circulation, and start a new tumor (metastatic tumor) somewhere else.

Find out more about Metastatic Melanoma Therapeutics Assessment @ Metastatic Melanoma Preclinical and Discovery Stage Products

Metastatic Melanoma Emerging Drugs Profile

• EVX 01: Evaxion Biotech
• IN 10018: InxMed
• AV MEL 1: AiVita Biomedical

Metastatic Melanoma Pipeline Therapeutics Assessment

There are approx. 75+ key companies which are developing the Metastatic Melanoma therapies. The Metastatic Melanoma companies which have their Metastatic Melanoma drug candidates in the most advanced stage, i.e. Phase II, Evaxion Biotech.

DelveInsight’s Metastatic Melanoma pipeline report covers around 75+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Metastatic Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Metastatic Melanoma Pipeline Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Learn more about the emerging Metastatic Melanoma Pipeline Therapies @ Metastatic Melanoma Clinical Trials Assessment

Scope of the Metastatic Melanoma Pipeline Report

• Coverage- Global
• Metastatic Melanoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Metastatic Melanoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Metastatic Melanoma Companies- Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralytics, Merck & Co., Neon Therapeutics, BioNTech, Bristol-Myers Squibb, Ono Pharmaceuticals, Cytovation AS, and others.
• Metastatic Melanoma Pipeline Therapies- TLPLDC Vaccine, EVX-01, Pembrolizumab 25 MG/ML, Nivolumab, IN10018, Cobimetinib, and others.

Dive deep into rich insights for new drugs for Metastatic Melanoma Treatment, Visit @ Metastatic Melanoma Market Drivers and Barriers, and Future Perspective

Table of Content

1. Introduction
2. Executive Summary
3. Metastatic Melanoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Metastatic Melanoma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. EVX 01: Evaxion Biotech
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. IN 10018: InxMed
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Metastatic Melanoma Key Companies
21. Metastatic Melanoma Key Products
22. Metastatic Melanoma- Unmet Needs
23. Metastatic Melanoma- Market Drivers and Barriers
24. Metastatic Melanoma- Future Perspectives and Conclusion
25. Metastatic Melanoma Analyst Views
26. Metastatic Melanoma Key Companies
27. 27.   Appendix

For further information on the Metastatic Melanoma Pipeline therapeutics, reach out to Metastatic Melanoma Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-melanoma-market